Your browser doesn't support javascript.
Seroprevalence of SARS-CoV-2 in Sweden, April 26 to May 9, 2021.
Beser, Jessica; Galanis, Ilias; Enkirch, Theresa; Kühlmann Berenzon, Sharon; van Straten, Edward; Duracz, Jan; Rapp, Marie; Zakikhany, Katherina; Mansjö, Mikael; Wigren Byström, Julia; Forsell, Mattias N E; Groenheit, Ramona; Tegmark Wisell, Karin; Bråve, Andreas.
  • Beser J; Public Health Agency of Sweden, Solna, Sweden. jessica.beser@folkhalsomyndigheten.se.
  • Galanis I; European Centre for Disease Prevention and Control (ECDC), European Public Health Microbiology Training Programme (EUPHEM), Solna, Sweden. jessica.beser@folkhalsomyndigheten.se.
  • Enkirch T; Public Health Agency of Sweden, Solna, Sweden.
  • Kühlmann Berenzon S; Public Health Agency of Sweden, Solna, Sweden.
  • van Straten E; Public Health Agency of Sweden, Solna, Sweden.
  • Duracz J; Public Health Agency of Sweden, Solna, Sweden.
  • Rapp M; Public Health Agency of Sweden, Solna, Sweden.
  • Zakikhany K; Public Health Agency of Sweden, Solna, Sweden.
  • Mansjö M; Public Health Agency of Sweden, Solna, Sweden.
  • Wigren Byström J; Public Health Agency of Sweden, Solna, Sweden.
  • Forsell MNE; Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
  • Groenheit R; Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
  • Tegmark Wisell K; Public Health Agency of Sweden, Solna, Sweden.
  • Bråve A; Public Health Agency of Sweden, Solna, Sweden.
Sci Rep ; 12(1): 10816, 2022 06 25.
Article in English | MEDLINE | ID: covidwho-1908297
ABSTRACT
A national point seroprevalence study of SARS-CoV-2 was conducted in Sweden in April-May 2021. In total, 2860 individuals 3 to 90 years old from a probability-based web panel were included. Results showed that an estimated 32.6% of the population in Sweden had detectable levels of antibodies, and among non-vaccinated 20.1% had detectable levels of antibodies. We tested for differences in seroprevalence between age groups and by sex and estimated seroprevalence among previously infected participants by time since reporting.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Randomized controlled trials Topics: Vaccines Limits: Adolescent / Adult / Aged / Child / Child, preschool / Humans / Middle aged / Young adult Country/Region as subject: Europa Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-15183-w

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Randomized controlled trials Topics: Vaccines Limits: Adolescent / Adult / Aged / Child / Child, preschool / Humans / Middle aged / Young adult Country/Region as subject: Europa Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-15183-w